Viking Therapeutics Set for Expansion with Promising Drug Developments
In a recent analysis, JPMorgan's Hardik Parikh has initiated coverage on Viking Therapeutics Inc (NASDAQ: VKTX) with an Overweight rating and a bold price target of $80 for December 2025. This outlook hints at a potential rise of about 45% from the current stock price of $54.65. The enthusiasm behind this prediction largely stems from Viking's cutting-edge obesity treatment candidate, oral-2735, which could make a significant mark in the fast-changing GLP-1 market.
Oral-2735: A Game-Changer in Managing Obesity
According to JPMorgan, oral-2735 has a strong chance of becoming a leading contender in the GLP-1 treatment arena, thanks in part to its high tolerability. Analyst Parikh cites Phase 1 clinical trial data showing that lower doses of oral-2735 are both efficacious and cause few gastrointestinal side effects.
There's also hope for the higher dose groups, which are expected to enhance both efficacy and tolerability. With estimates suggesting that the U.S. GLP-1 market could reach $120 billion by 2030, Parikh anticipates that oral-2735 might capture around 10% of the oral obesity treatment segment. This promising position indicates that the market may not yet fully grasp the potential of oral-2735, setting the stage for a strong increase in Viking's stock.
Upcoming Milestones: Obesity Week This November
JPMorgan has put Viking Therapeutics on its “positive catalyst watch” as it approaches the Phase 1 readout scheduled for Obesity Week in November 2024. Parikh encourages investors to consider holding onto VKTX shares as the readout date nears. He forecasts that the resulting data could trigger a dramatic increase in stock prices, projecting a possible surge of 30-60% following the latest findings.
Moreover, with oral-2735 expected to hit the market by 2030, JPMorgan predicts that U.S. sales could reach $1 billion by 2035. Thanks to its strong competitive advantages and good tolerability, Viking Therapeutics appears well-positioned to play a major role in the expanding obesity treatment sector.
Looking to the Future: VKTX and Obesity Treatment
For investors interested in Viking Therapeutics, the data release focused on oral-2735 could mark a crucial turning point. Parikh sees considerable upside potential for VKTX stock as the wider market starts recognizing the promise of oral-2735. The excitement surrounding this candidate may translate into real gains for investors.
As Viking Therapeutics continues to navigate these encouraging developments, there's a sense of optimism about its potential to broaden its product lines and enhance its role in the healthcare marketplace.
Frequently Asked Questions
What is oral-2735?
Oral-2735 is an obesity treatment under development by Viking Therapeutics, currently being studied for its potential effectiveness in the GLP-1 market.
Why is JPMorgan optimistic about VKTX stock?
The optimism largely comes from the drug's potential to serve as an innovative treatment in a high-demand market, coupled with promising results from clinical trials.
When will the Phase 1 readout for oral-2735 take place?
The Phase 1 readout is slated for November 2024, coinciding with Obesity Week.
What are the expected market projections for the GLP-1 sector?
The U.S. GLP-1 market is expected to surpass $120 billion by 2030, with oral-2735 anticipated to capture a significant portion of the market.
How might the results from the Phase 1 trial affect the stock price?
Favorable results could lead to a sharp increase in VKTX's stock value, potentially rising by 30-60% in response to the data release.
